ページ5 - トルコで最高の腫瘍科医師 - トップ198名の医師

Education and Specialization

2017 Istanbul University Istanbul Faculty of Medicine, Department of Internal Medicine, Department of Internal Medicine

19 November 2020 Istanbul University Istanbul Faculty of Medicine, Department of Medical Oncology

2011-25 June 2015 Hospitals / Istanbul Haydarpasa Numune Education and Research Hospital

2004 Mersin University Faculty of Medicine

Experience

13.11.2017-29.03.2021 Istanbul University Istanbul Faculty of Medicine Internal Medicine Departments, Department of Internal Medicine

21.03.2011-25.06.2015 Istanbul Haydarpasa Numune Education and Research Hospital



Ferhatoğlu Ferhat, Çağatay Tulin, Okumuş Nigar Gülfer, Aydıner Adnan, Paksoy Nail, Ak Naziye, Aydın Esra, Saip Pinar Mualla (2023). Laterality Of Adrenal Gland Metastasis In Lung Cancer: Results Of A Comparative Study. Eurasian Journal Of Medical Investigatin, 7(2), 101-106., Doi: 10.14744/Ejmi.2023.58954

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

TAŞTEKİN DİDEM, PAKSOY NAİL, DOĞAN İZZET, FERHATOĞLU FERHAT, KHANMAMMADOV NIJAT, BOZBEY HAMZA UGUR, KARABULUT SENEM (2023). Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first?line treatment of metastatic gastric cancer: A single?center experience. Journal of Cancer Research and Therapeutics, 19(2), 253-258., Doi: 10.4103/jcrt.jcrt_672_22 (Quarterly=Q4)

KAPAĞAN TANJU, FERHATOĞLU FERHAT (2023). Prognostic Factors for Intensive Care Unit (ICU) Admission among Hospitalized Gastrointestinal and Hepatopancreatobiliary Cancer Patients with Systemic Urinary Tract Infection. Eurasian Journal of Medical Investigation, 7(2), 107-115., Doi: 10.14744/ejmi.2023.81340

KAPAĞAN TANJU, FERHATOĞLU FERHAT (2023). Prognostic Factors for Intensive Care Unit (ICU) Admission among Hospitalized Gastrointestinal and Hepatopancreatobiliary Cancer Patients with Systemic Urinary Tract Infection. Eurasian Journal of Medical Investigation, 7(2), 107-115., Doi: 10.14744/ejmi.2023.81340

FERHATOĞLU FERHAT, AYDINER ADNAN, PAKSOY NAİL (2022). Evaluation of clinical features and risk factors related to late recurrence (>5 years) in patients with breast cancer. Journal of Surgery and Medicine, 6(12), 986-990., doi: 10.28982/josam.7610

FERHATOĞLU FERHAT, ERTÜRK KAYHAN, TAŞ FARUK (2022). Cutaneous melanoma survival rates of the elderly are not worse than those of the young, yet they have some specific differences. Journal of Cancer Research and Therapeutics, 0, Doi: 10.4103/jcrt.jcrt_815_21

ÖZGÜR EMRE, FERHATOĞLU FERHAT, ŞEN FATMA, GEZER UĞUR (2022). Effect of Cytotoxic Therapy on ALU Expression is Modulated by Hormonal Status in Patients with Breast Cancer. BALKAN MEDICAL JOURNAL, 39(6), 450-451., Doi: 10.4274/balkanmedj.galenos.2022.2022-5-18

Articles

TAŞ FARUK, ERTÜRK KAYHAN, FERHATOĞLU FERHAT (2022). Auricular and periauricular melanomas have similar clinicopathologic factors and survival rates. JOURNAL OF COSMETIC DERMATOLOGY, 21(4), 1570-1573., Doi: 10.1111/jocd.14278

TAŞ FARUK, ERTÜRK KAYHAN, FERHATOĞLU FERHAT (2022). Completion Lymph Node Dissection Is Unnecessary After Positive Sentinel Lymph Node in Melanoma — a Case Series Analysis. Indian Journal of Surgery, Doi: 10.1007/s12262-022-03532-y

DOĞAN İZZET, GÜRBÜZ MUSTAFA, PAKSOY NAİL, FERHATOĞLU FERHAT, VATANSEVER SEZAİ, SAİP PINAR, DEMİRKAZIK AHMET, AYDINER ADNAN (2022). Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC. Medicine, 101(34), 30188, Doi: 10.1097/MD.0000000000030188

PAKSOY NAİL, KHANMAMMADOV NIJAT, DOĞAN İZZET, FERHATOĞLU FERHAT, YILDIZ ANIL, AK NAZİYE, AYDINER ADNAN (2022). Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study. Medicine, 101(45), 31726, Doi: 10.1097/MD.0000000000031726

PAKSOY NAİL, FERHATOĞLU FERHAT, DOĞAN İZZET, KHANMAMMADOV NIJAT, İRİBAŞ ÇELİK AYÇA, GÜLBAŞ ZAFER, BAŞARAN MERT (2022). High-dose chemotherapy followed by autologous stem cell transplantation for adult patients With first relapse of Ewing's sarcoma: A single institution experience. Medicine, 101(49), 32213, Doi: 10.1097/MD.0000000000032213

ÇİL İBRAHİM, KÜÇÜKARDA AHMET, ATCI MUHAMMED MUSTAFA, SECMELER SABAN, PAKSOY NAİL, FERHATOĞLU FERHAT, AK NAZİYE, AYHAN MURAT, TATAROĞLU ÖZYÜKSELER DENİZ, ÖNDER ARİF HAKAN, AVCI OKAN, OYMAN ABDİLKERİM, OKTEN ILKER NIHAT, GÜLTÜRK İLKAY, AKAGÜNDÜZ BARAN, BASOĞLU TÜYLÜ TUĞBA, ÇAKIR EMRE, HACIBEKİROĞLU İLHAN, ÖZÇELİK MELİKE, AYDINER ADNAN (2022). Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori Journal, 108(1), 19-25., Doi: 10.1177/03008916211037739

DOĞAN İZZET, KARABULUT SENEM, TAŞTEKİN DİDEM, FERHATOĞLU FERHAT, PAKSOY NAİL, ŞAKAR BURAK (2022). Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer. Journal of the College of Physicians and Surgeons Pakistan, 32(8), 1014-1019., Doi: 10.29271/jcpsp.2022.08.1014

FERHATOĞLU FERHAT, TUĞCU MURAT, APAYDIN SÜHEYLA (2022). Factors Affecting Postoperative Morbidity and Mortality in Chronic Hemodialysis Patients. Eurasian Journal of Medical Advances, 2(3), 30-38., doi: 10.14744/ejma.2022.43153

KAPAĞAN TANJU, FERHATOĞLU FERHAT, RETIRED SELİNAY, KILIÇ ÇAĞLA ECEM (2022). Risk Factors for Cutaneous Melanomas and Level of Awareness in Society. Journal of the Turkish Academy of Dermatology, 16(4), 94-100., Doi: 10.4274/jtad.galenos.2022.30092

FERHATOĞLU FERHAT, ALTAN FERHATOĞLU ZEYNEP (2022). Frequency, Demographic and Clinicopathological Characteristics of Skin Cancer Patients Treated and Followed Up in the Medical Oncology Outpatient Clinic. Journal of the Turkish Academy of Dermatology, 16(4), 77-81., Doi: 10.4274/jtad.galenos.2022.04706

KARABULUT SENEM, DOĞAN İZZET, USUL AFŞAR ÇİĞDEM, KARABULUT MEHMET, KARAMAN ŞULE, FERHATOĞLU FERHAT, TAŞTEKİN DİDEM (2021). Does nutritional status affect treatment tolarability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 27(6), 1357- 1363., Doi: 10.1177/1078155220959427

AK NAZİYE, ÖZKAN BERKER, YENİGÜN BÜLENT MUSTAFA, YILMAZBAYHAN EMİNE DİLEK, TOKER SEYFİ ALPER, FERHATOĞLU FERHAT, YAŞAR HATIME ARZU, DİZBAY SAK SERPİL, TANJU SERHAT, DILEGE MUSTAFA ŞÜKRÜ, ERUS SUAT, BULUTAY PINAR, FIRAT PINAR, MANDEL NİL MOLİNAS, KILIÇKAP SAADETTİN, ONDER SEVGEN, DİKMEN ERKAN, ALAN ÖZKAN, YUMUK PERRAN FULDEN, BOZKURTLAR EMİNE, LAÇİN TUNÇ, YILDIZELİ BEDRETTİN, ÖZTÜRK AKIN, KOCATÜRK CELALETTİN İBRAHİM, KARAPINAR KEMAL, ÜRER HALIDE NUR, OYAN ULUÇ BAŞAK, AYDINER ADNAN, DEMİRKAZIK AHMET, ERALP YEŞİM (2021). The role of adjuvant chemotherapy in resected stage I non-small cell lung cancer: A Turkish Oncology Group Study.. Journal of BUON, 26(3), 819-829.

AK NAZİYE, TOKER SEYFİ ALPER, KARA MURAT, ÖZKAN BERKER, ÜLKER MELİKE GÜLER, KABA ERKAN, YEGEN GÜLÇİN, KARAMAN ŞULE, DAĞOĞLU SAKİN RABİA NERGİZ, KAYTAN SAGLAM ESRA, ORAL ETHEM NEZİH, KİZİR AHMET, BAYRAKTAR SOLEY, DİSTÇİ RIAN, FERHATOĞLU FERHAT, AYDIN ESRA, VATANSEVER SEZAİ, ERALP YEŞİM, AYDINER ADNAN (2021). Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center. TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 29(4), 487- 495., Doi: 10.5606/tgkdc.dergisi.2021.20529

AK NAZİYE, PAKSOY NAİL, FERHATOĞLU FERHAT, AYDIN ESRA, DOĞAN İZZET, BEKTAŞ ERDEM, KARACA MERT, OGUZ SOYDİNÇ HİLAL, MINARECİ YAĞMUR, SÖZEN HAMDULLAH, TOPUZ SAMET, SAİP PINAR MUALLA, VATANSEVER SEZAİ (2021). Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma. TURKISH JOURNAL of ONCOLOGY, 36(4), 438-445., Doi: 10.5505/tjo.2021.2882

Dr. Saban Sec is a medical oncologist with experience at leading hospitals, including Haseki Training and Research Hospital, Prof. Dr. Cemil Taşcıoğlu City Hospital, and Bahçelievler Medikalpark Hospital. He currently represents specialist physicians in the Turkish Medical Oncology Association. He is also a member of the Istanbul Medical Chamber and the Turkish Medical Oncology Association.

Dr. Sec treats breast, lung, gastrointestinal, prostate, urogenital, head and neck cancers, as well as sarcomas and rare tumors. He has published many peer-reviewed articles on cancer prognosis, treatment outcomes, and survival rates. His research includes studies with large patient groups, such as 138 patients with HER2-positive metastatic gastric cancer. Dr. Sec focuses on prognostic factors and treatment responses in different cancers. He is dedicated to improving cancer care.

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Fields of Study and Interests

 Breast Cancer

 Lung Cancer

 Colon Cancer

 Stomach Cancer

 Rectum Cancer

 Ovarian Cancer

 Uterine Cancer

 Liver Cancer

 Esophageal Cancer - Esophagus Cancer

 Kidney Cancer

 Larynx Cancer - Throat Cancer

 Thyroid Cancer

 Head and Neck Cancers

 Gynecological Cancers

 Pancreatic Cancer

 Esophageal Cancer - Esophagus Cancer

 Uterine Cancer

 Brain Cancers - Brain Tumors

 Soft Tissue Cancer - Sarcomas

 Prostate Cancer

 Bladder Cancer

 Bile Duct Cancer

 Testicular Cancer

 Cervical Cancer

 Mouth, Tongue, Lip Cancers

 Gastrointestinal System Cancers

 Bone Tumors

 Trachea and Bronchial Cancers

 Skin Cancers - Skin Cancers

 Skeletal System Tumors

 Gallbladder Cancer

 Mesothelioma

Education

 Cumhuriyet University Faculty of Medicine, 2004

 Istanbul Haydarpaşa Education and Research Hospital Internal Medicine Specialist, 2010

 Karadeniz Technical University Faculty of Medicine Medical Oncology Specialist, 2015

Career

 MD Andeson Cancer Center, USA, 2008

 Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017

 Moffit Cancer Center, USA 2022

 Istanbul Haydarpaşa Education and Research Hospital Internal Medicine, 2010

 İdil State Hospital Internal Medicine Clinic, 2011

 Karadeniz Technical University Faculty of Medicine Medical Oncology Clinic, 2015

 Istanbul Göztepe Education and Research Hospital Medical Oncology Clinic, 2018

 Yeniyüzyıl University Gaziosmanpaşa Hospital Medical Oncology Clinic, 2020

 Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

EXPERIENCE

2019 - Present, Istanbul/Istanbul/Turkey

MEMORIAL ATAŞEHİR HOSPITAL

General Surgeon

2012 - 2019, Diyarbakır/Diyarbakır/Turkey

DİCLE UNIVERSITY FACULTY OF MEDICINE

General Surgeon

2011 - 2012, Van/Van/Turkey

VAN REGIONAL TRAINING AND RESEARCH HOSPITAL

General Surgeon

2009 - 2011, Van/Van/Turkey

HAKKARİ STATE HOSPITAL

General Surgeon

2004 - 2009, Van/Van/Turkey

YÜZÜNCÜYIL UNIVERSITY FACULTY OF MEDICINE

General Surgeon

2002 - 2004, Van/Van/Turkey

HACIBEKİR HEALTH CENTER

General Practitioner

EDUCATION

2018 - 2019, Diyarbakır/Turkey

Associate Professor

2015, Ohio/USA

OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Neck Dissection Training

2012 - 2018, Diyarbakır/Turkey

Assistant Professor

1996 - 2002, Adana/Turkey

ÇUKUROVA UNIVERSITY

FACULTY OF MEDICINE - Medical Doctor Education

Dr. Omer Uslukaya is the author of 50 scientific publications in general and reconstructive surgery, focusing on laparoscopic splenectomy, pancreatitis, wound healing, and breast surgery outcomes.

Urologist

• 2021 - 2021, Istanbul/Turkey
  SEYRANTEPE HAMİDİYE ETFAL HOSPITAL
  General Surgery Specialist
• 2021 - Currently, Istanbul/Turkey
  MEMORIAL HİZMET HOSPITAL
  General Surgery Specialist
• 2021 - Currently, Istanbul/Turkey
  MEMORIAL ATAŞEHİR HOSPITAL
  General Surgery Specialist
• 2014 - 2014, Istanbul/Turkey
  BEZMIALEM UNIVERSITY
  General Surgery Specialist
• 2013 - 2013, /ABD
  ST-MARY HOSPİTAL
  General Surgery Specialist
• 2009 - 2009, Istanbul/Turkey
  BÜYÜKÇEKMECE PUBLIC HOSPITAL
  General Surgery Specialist
• 2009 - 2021, Istanbul/Turkey
  SISLI HAMİDİYE ETFAL HOSPITAL
  General Surgery Specialist

Professor of oncosurgery and proctology

EXPERIENCE

2024 - Present, Istanbul, Turkey

MEMORIAL ATAŞEHİR HOSPITAL

Medical Oncology Specialist

2016 - 2024, Istanbul, Turkey

MARMARA UNIVERSITY PENDIK TRAINING AND RESEARCH HOSPITAL

2015 - 2016, Kocaeli, Turkey

KOCAELİ STATE HOSPITAL

Compulsory Service

2011 - 2014, Istanbul, Turkey

DR. LÜTFİ KIRDAR TRAINING AND RESEARCH HOSPITAL

2010 - 2011, Sinop, Turkey

SİNOP DURAĞAN STATE HOSPITAL

Compulsory Service

2004 - 2010, Istanbul, Turkey

ISTANBUL UNIVERSITY CERRAHPAŞA FACULTY OF MEDICINE

EDUCATION

2020 - Present

Marmara University Pendik Training and Research Hospital

Associate Professorship in Medical Oncology

2011 - 2014, Istanbul, Turkey

Dr. Lütfi Kırdar Training and Research Hospital

Medical Oncology Specialization

2004 - 2010, Istanbul, Turkey

Istanbul University Cerrahpaşa Faculty of Medicine

Internal Medicine Specialization

1997 - 2003, Istanbul, Turkey

Istanbul University Cerrahpaşa Faculty of Medicine

Medical Education

SCIENTIFIC PUBLICATIONS

• 63 articles published in journals indexed in international databases (first author in 11 of them).

• Over 100 presentations at international and national congresses.

• 4 review articles published in national journals (first author in 3 of them).

• Authorship of 1 book chapter and co-editorship of 1 book.

Dermatologist

Medical Oncology

Fields of Study and Interests

 Gastrointestinal System (GI) Cancer

 Cancer Vaccines

 Breast Cancers

 Lung Cancer

 Rare Cancers

Education

 MD: Necmettin Erbakan University Meram Faculty of Medicine, 1994

 Internal Medicine Specialist Training: Atatürk University Faculty of Medicine, 2004

 Internal Medicine Specialist Training: Kafkas University Faculty of Medicine, 2007

 Medical Oncology Sub-Specialist Training: Selçuk University Faculty of Medicine, 2010

 Medical Oncology Sub-Specialist Training: Istanbul University Oncology Institute, 2013

Career

 Assistant Professor: Atatürk University Faculty of Medicine, 2005

 Assist. Prof. Dr.: Kafkas University, 2006-2007

 Minor Assistant Professor: Selçuk University – Medical Oncology, 2007-2010

 Minor Assistant Professor: Istanbul University Oncology Institute – Medical Oncology,

2012-2013

 Specialist Professor: Istanbul University Oncology Institute – Medical Oncology, 2013-2017

 Assoc. Prof. Dr.: Istanbul University Oncology Institute – Medical Oncology, 2017-2023

 Prof. Dr.: Istanbul University Oncology Institute – Medical Oncology, 2023-present

Education and Residency

2001 to 2007: Medical Education, Meram School of Medicine, Selçuk University

2009 to 2014: Residency Education, School of Medicine, Atatürk University

Experience

2009 to 2014: Residency, Department of Orthopedics and Traumatology, School of Medicine, Atatürk University

2015 to 2016: Conscription, Kozluk State Hospital, Batman

2016: Orthopedic Oncology, Experience Trainings, Ibn-I Sina Hospital, Ankara University

2017: Orthopedic Oncology, Experience Trainings, Acıbadem Medical School

2021: Orthopedic Oncology Training, Acıbadem Medical School

Professional Memberships

-Association of Bone and Soft Tissue Tumors

-Association of Hip and Knee Arthroplasty

-Foot and Ankle Surgery Department

-Association of Extremity Reconstruction and Ilizarov Methods Development

-Federation of Turkish Society of Orthopedics and Traumatology (TOTBID)

Education & Expertise

• 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
• 2005 to 2009 – Düzce University, Internal Medicine Specialization
• 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
• 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
• 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
• 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
• 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
• 2020 to Present – Professor, Sakarya University Faculty of Medicine
• 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

Experience

• 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
• 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

Professional Memberships

• TTOD (Turkish Society of Medical Oncology)
• ASCO (American Society of Clinical Oncology)
• ESMO (European Society for Medical Oncology)

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

• 2004-2011: İnönü University Faculty of Medicine
• 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
• 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

• 2016-2017: Bingöl City Hospital, Internal Medicine
• 2021-2022: Health Sciences University, Medical Oncology
• 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
• 2023-2024: Ohio State University, Medical Oncology
• 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

• 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
• 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

• 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
• 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
• 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
• 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
• 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

• Ongoing: ECFMG Certification
• 2024: CITI Responsible Conduct of Research (The Ohio State University)
• 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
• 2024: CITI Human Subjects Protection (The Ohio State University)
• 2024: CITI Good Clinical Practice (The Ohio State University)
• 2023: Occupational English Test (OET)
• 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
• 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
• 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

• American Society of Clinical Oncology (ASCO) - 2022
• Turkish Society of Medical Oncology - 2020

Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.